Immunome Q2 2026 net loss widens to $73.1 million; no collaboration revenue
Immunome reported second-quarter 2026 results with a net loss of $73.1 million, up from $43.4 million a year earlier, as it booked no collaboration revenue against $4.0 million in the prior-year quarter. Higher research and development and general and administrative spending drove the increase, and the company said its cash position is expected to fund operations into 2028.
Key points
- Net loss of $73.1 million, or $0.65 per share, for the quarter ended June 30, 2026, versus $43.4 million, or $0.50 per share, a year earlier
- Collaboration revenue was $0 versus $4.0 million in the prior-year quarter
- Research and development expenses rose to $59.9 million from $40.5 million; general and administrative expenses rose to $18.3 million from $10.0 million
- Cash, cash equivalents and marketable securities totaled $520.0 million as of June 30, 2026; the company expects this to fund operations into 2028
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.